Experimental drug treatments for hepatocellular carcinoma: clinical trial failures 2015 to 2021

References

• Forner A, Reig M, Bruix J.Hepatocellular carcinoma.Lancet.2018Mar31;391:1301–1314. London,England10127 https://doi.org/10.1016/S0140-6736(18)30010-2
   PubMed Web of Science ®Google Scholar
• Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016 Apr 14;2:16018. https://doi.org/10.1038/nrdp.2016.18.
   Google Scholar
• Reig M, Á D-G, Bruix J. The success of regorafenib in hepatocellular carcinoma in a world of failures. Learn future dev Oncotarget. 2017 Dec 5. 863:106151–106152.
   Google Scholar
• Maluccio MA, Covey AM, Porat LB, et al. Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2008 Jun;19(6):862–869. https://doi.org/10.1016/j.jvir.2008.02.013.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002 May 18 359(9319):1734–1739. https://doi.org/10.1016/S0140-6736(02)08649-X
   Google Scholar
• Maluccio M, Covey AM, Gandhi R, et al. Comparison of survival rates after bland arterial embolization and ablation versus surgical resection for treating solitary hepatocellular carcinoma up to 7 cm. J Vasc Interv Radiol. 2005 Jul;16(7):955–961. https://doi.org/10.1097/01.RVI.0000161377.33557.20.
   PubMed Web of Science ®Google Scholar
• Raoul JL, Forner A, Bolondi L, et al. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev. 2019 Jan;72:28–36.
   PubMed Web of Science ®Google Scholar
• Benson AB, D’Angelica MI, Abbott DE, et al. Hepatobiliary cancers,version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021 May 1 19(5):541–565. https://doi.org/10.6004/jnccn.2021.0022
   Google Scholar
• Greten TF, Lai CW, Li G, et al. Targeted and immune-based Therapies for hepatocellular carcinoma. Gastroenterology. 2018 Oct 1;156:510–524. https://doi.org/10.1053/j.gastro.2018.09.051.
   Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24;359(4):378–390. https://doi.org/10.1056/NEJMoa0708857.
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. (London, England). 2018 Mar 24;391(10126):1163–1173. https://doi.org/10.1016/S0140-6736(18)30207-1.
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020 May 14;382(20):1894–1905. https://doi.org/10.1056/NEJMoa1915745.
   PubMed Web of Science ®Google Scholar
• Lee MS, Ryoo BY, Hsu CH, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020 Jun;21(6):808–820. DOI:https://doi.org/10.1016/S1470-2045(20)30156-X.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022 Apr;76(4):862–873. DOI:https://doi.org/10.1016/j.jhep.2021.11.030.
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Jan 07;389(10064):56–66. https://doi.org/10.1016/S0140-6736(16)32453-9.
   PubMed Web of Science ®Google Scholar
• Kelley RK, Ryoo BY, Merle P, et al. Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. ESMO Open. 2020 Aug;5(4):e000714. DOI:https://doi.org/10.1136/esmoopen-2020-000714.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Park JO, Ryoo BY, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015 Jul;16(7):859–870. https://doi.org/10.1016/S1470-2045(15)00050-9.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Feb;20(2):282–296. DOI:https://doi.org/10.1016/S1470-2045(18)30937-9.
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. The Lancet. (London, England). 2017 Apr 20;389:2492–2502. https://doi.org/10.1016/S0140-6736(17)31046-2.
   Google Scholar
• Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018 Jun 1;19:940–952. https://doi.org/10.1016/S1470-2045(18)30351-6.
   Google Scholar
• Zhang J, Zong Y, Xu GZ, et al. Erlotinib for advanced hepatocellular carcinoma. A systematic review of phase II/III clinical trials. Saudi Med J. 2016 Nov;37(11):1184–1190. https://doi.org/10.15537/smj.2016.11.16267.
   PubMedGoogle Scholar
• Kaseb AO, Morris JS, Iwasaki M, et al. Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. Onco Targets Ther. 2016;9:773–780.
   PubMed Web of Science ®Google Scholar
• Thomas MB, Garrett-Mayer E, Anis M, et al. A randomized phase ii open-label multi-institution study of the combination of bevacizumab and erlotinib compared to sorafenib in the first-line treatment of patients with advanced hepatocellular carcinoma. Oncology. 2018;94(6):329–339. https://doi.org/10.1159/000485384.
   PubMed Web of Science ®Google Scholar
• He L, Deng H, Lei J, et al. Efficacy of bevacizumab combined with erlotinib for advanced hepatocellular carcinoma: a single-arm meta-analysis based on prospective studies. BMC Cancer. 2019 Mar 28 19(1):276. https://doi.org/10.1186/s12885-019-5487-6
   Google Scholar
• Kang YK, Yau T, Park JW, et al. Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. Ann Oncol. 2015 Dec;26(12):2457–2463. DOI:https://doi.org/10.1093/annonc/mdv388.
   PubMed Web of Science ®Google Scholar
• McNamara MG, Le LW, Horgan AM, et al. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma. Cancer. 2015 May 15 121(10):1620–1627. https://doi.org/10.1002/cncr.29227
   Google Scholar
• Lin ZZ, Chen BB, Hung YP, et al. A multicenter phase ii study of second-line axitinib for patients with advanced hepatocellular carcinoma failing first-line sorafenib monotherapy. Oncologist. 2020 Sep;25(9):e1280–e1285. DOI:https://doi.org/10.1634/theoncologist.2020-0143.
   PubMedGoogle Scholar
• Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018 Sep 19 11(1):120. https://doi.org/10.1186/s13045-018-0664-7
   Google Scholar
• Sun Y, Zhou A, Zhang W, et al. Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study). Hepatol Int. 2021 Jun;15(3):621–629. DOI:https://doi.org/10.1007/s12072-021-10171-0.
   PubMed Web of Science ®Google Scholar
• Hou Z, Zhu K, Yang X, et al. Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial. Ann Transl Med. 2020 Sep;8(17):1047. DOI:https://doi.org/10.21037/atm-20-2990.
   PubMedGoogle Scholar
• Qin S, Li Q, Gu S, et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2021 Jul;6(7):559–568. DOI:https://doi.org/10.1016/S2468-1253(21)00109-6.
   PubMed Web of Science ®Google Scholar
• Linifanib.Drugs R D. 2010;10(2):111–122. doi:https://doi.org/10.2165/11584520-000000000-00000.
   PubMedGoogle Scholar
• Cainap C, Qin S, Huang WT, et al. Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol. [2015 Jan 10];33(2):172–179.
   PubMedGoogle Scholar
• Cheng AL, Thongprasert S, Lim HY, et al. Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. Hepatology. 2016 Sep;64(3):774–784.
   PubMed Web of Science ®Google Scholar
• Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006 Aug;5(8):671–688.
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan SL, Mo FK, et al. Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response. BMC Cancer. 2015 May 12;15:395. https://doi.org/10.1186/s12885-015-1334-6.
   Google Scholar
• Knox JJ, Qin R, Strosberg JR, et al. A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma. Invest New Drugs. 2015 Feb;33(1):241–246. DOI:https://doi.org/10.1007/s10637-014-0169-3.
   PubMed Web of Science ®Google Scholar
• Sanoff HK, Kim R, Ivanova A, et al. Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma. Invest New Drugs. 2015 Apr;33(2):505–509. DOI:https://doi.org/10.1007/s10637-015-0209-7.
   PubMedGoogle Scholar
• Feun LG, Wangpaichitr M, Li YY, et al. Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma. J Hepatocell Carcinoma. 2018;5:9–15.
   PubMed Web of Science ®Google Scholar
• Qin S, Chan SL, Sukeepaisarnjaroen W, et al. A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma. Ther Adv Med Oncol. 2019;11:1758835919889001.
   Web of Science ®Google Scholar
• Rimassa L, Assenat E, Peck-Radosavljevic M, et al. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol. 2018 May;19(5):682–693. DOI:https://doi.org/10.1016/S1470-2045(18)30146-3.
   PubMed Web of Science ®Google Scholar
• Weekes CD, Clark JW, Zhu AX. Tivantinib for advanced hepatocellular carcinoma: is MET still a viable target? Lancet Oncol. 2018 May;19(5):591–592.
   PubMedGoogle Scholar
• Watermann I, Schmitt B, Stellmacher F, et al. Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation? Diagn Pathol. 2015 Jul 28;10:130. https://doi.org/10.1186/s13000-015-0362-5.
   Google Scholar
• Kim JH, Kim HS, Kim BJ, et al. Prognostic value of c-Met overexpression in hepatocellular carcinoma: a meta-analysis and review. Oncotarget. 2017 Oct 27 8(52):90351–90357. https://doi.org/10.18632/oncotarget.20087
   Google Scholar
• Yau TCC, Lencioni R, Sukeepaisarnjaroen W, et al. A phase i/ii multicenter study of single-agent foretinib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res off J Am Assoc Cancer Res. 2017 May 15 23(10):2405–2413. https://doi.org/10.1158/1078-0432.CCR-16-1789
   Google Scholar
• Tai WM, Yong WP, Lim C, et al. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC). Ann Oncol. 2016 Dec;27(12):2210–2215. DOI:https://doi.org/10.1093/annonc/mdw415.
   PubMed Web of Science ®Google Scholar
• Palmer DH, Ma YT, Peck-Radosavljevic M, et al. A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma. Br J Cancer. 2018 May;118(9):1162–1168. DOI:https://doi.org/10.1038/s41416-018-0051-8.
   PubMed Web of Science ®Google Scholar
• Fountzilas C, Gupta M, Lee S, et al. A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma. Br J Cancer. 2020 Mar;122(7):963–970. DOI:https://doi.org/10.1038/s41416-020-0737-6.
   PubMedGoogle Scholar
• Qin S, Bi F, Gu S, et al. Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase II-III trial. J Clin Oncol. 2021 Sep 20 39(27):3002–3011. https://doi.org/10.1200/JCO.21.00163
   PubMed Web of Science ®Google Scholar
• Kudo M, Moriguchi M, Numata K, et al. S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial. Lancet Gastroenterol Hepatol. 2017 Jun;2(6):407–417. DOI:https://doi.org/10.1016/S2468-1253(17)30072-9.
   PubMed Web of Science ®Google Scholar
• Nagano H, Obi S, Hatano E, et al. Multicenter, randomized, controlled trial of S-1 monotherapy versus S-1 and interferon-α combination therapy for hepatocellular carcinoma with extrahepatic metastases. Hepatol Res. 2018 Aug;48(9):717–726. DOI:https://doi.org/10.1111/hepr.13067.
   PubMedGoogle Scholar
• Lee DW, Lee KH, Kim HJ, et al. A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma. BMC Cancer. 2018 Mar 5 18(1):252. https://doi.org/10.1186/s12885-018-4039-9
   Google Scholar
• Patt YZ, Murad W, Fekrazad MH, et al. INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter phase II trial. Cancer Med. 2017 Sep;6(9):2042–2051. DOI:https://doi.org/10.1002/cam4.1138.
   PubMedGoogle Scholar
• Patt Y, Rojas-Hernandez C, Fekrazad HM, et al. Phase II trial of sorafenib in combination with capecitabine in patients with hepatocellular carcinoma: INST 08-20. Oncologist. 2017 Oct;22(10):1158–e116. DOI:https://doi.org/10.1634/theoncologist.2017-0168.
   PubMedGoogle Scholar
• Changou CA, Shiah HS, Chen LT, et al. A phase II clinical trial on the combination therapy of PHY906 plus capecitabine in hepatocellular carcinoma. Oncologist. 2021 Mar;26(3):e367–e373. DOI:https://doi.org/10.1002/onco.13582.
   PubMed Web of Science ®Google Scholar
• Gabrielson A, Tesfaye AA, Marshall JL, et al. Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2015 Nov;76(5):1073–1079. DOI:https://doi.org/10.1007/s00280-015-2852-2.
   PubMed Web of Science ®Google Scholar
• Sho T, Nakanishi M, Morikawa K, et al. A phase I study of combination therapy with sorafenib and 5-fluorouracil in patients with advanced hepatocellular carcinoma. Drugs R D. 2017 Sep;17(3):381–388. DOI:https://doi.org/10.1007/s40268-017-0187-7.
   PubMed Web of Science ®Google Scholar
• Goyal L, Zheng H, Abrams TA, et al. A phase II and biomarker study of sorafenib combined with modified folfox in patients with advanced hepatocellular carcinoma. Clin Cancer Res off J Am Assoc Cancer Res. 2019 Jan 1 25(1):80–89. https://doi.org/10.1158/1078-0432.CCR-18-0847
   Google Scholar
• Harding JJ, Yang TS, Chen YY, et al. Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: results of an international, single-arm, phase 2 study. Cancer. 2021 Dec 15 127(24):4585–4593. https://doi.org/10.1002/cncr.33870
   Google Scholar
• Yau T, Cheng PNM, Chiu J, et al. A phase 1 study of pegylated recombinant arginase (PEG-BCT-100) in combination with systemic chemotherapy (capecitabine and oxaliplatin)[PACOX] in advanced hepatocellular carcinoma patients. Invest New Drugs. 2021 Nov 4;40:314–321. https://doi.org/10.1007/s10637-021-01178-3.
   Google Scholar
• Liu Y, Yue H, Xu S, et al. First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study. Int J Clin Oncol. 2015 Oct;20(5):952–959. DOI:https://doi.org/10.1007/s10147-015-0796-5.
   PubMedGoogle Scholar
• Assenat E, Pageaux GP, Thézenas S, et al. Sorafenib alone vs. sorafenib plus GEMOX as 1(st)-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial. Br J Cancer. 2019 Apr;120(9):896–902. DOI:https://doi.org/10.1038/s41416-019-0443-4.
   PubMed Web of Science ®Google Scholar
• Azim HA, Omar A, Atef H, et al. Sorafenib plus tegafur-uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study). J Hepatocell Carcinoma. 2018;5:109–119.
   PubMed Web of Science ®Google Scholar
• El Dika I, Capanu M, Chou JF, et al. Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib. Cancer Med. 2020 Oct;9(20):7453–7459. DOI:https://doi.org/10.1002/cam4.3389.
   PubMedGoogle Scholar
• Zhu AX, Rosmorduc O, Evans TR, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015 Feb 20 33(6):559–566. https://doi.org/10.1200/JCO.2013.53.7746
   Google Scholar
• Hubbard JM, Mahoney MR, Loui WS, et al. Phase I/II randomized trial of sorafenib and bevacizumab as first-line therapy in patients with locally advanced or metastatic hepatocellular carcinoma: north central cancer treatment group trial N0745 (alliance). Target Oncol. 2017 Apr;12(2):201–209. DOI:https://doi.org/10.1007/s11523-016-0467-0.
   PubMed Web of Science ®Google Scholar
• Koeberle D, Dufour JF, Demeter G, et al. Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). Ann Oncol. 2016 May;27(5):856–861. DOI:https://doi.org/10.1093/annonc/mdw054.
   PubMed Web of Science ®Google Scholar
• Kelley RK, Joseph NM, Nimeiri HS, et al. Phase II trial of the combination of temsirolimus and sorafenib in advanced hepatocellular carcinoma with tumor mutation profiling. Liver Cancer. 2021 Nov;10(6):561–571. DOI:https://doi.org/10.1159/000518297.
   PubMedGoogle Scholar
• Adjei AA, Richards DA, El-Khoueiry A, et al. A phase I study of the safety, pharmacokinetics, and pharmacodynamics of combination therapy with refametinib plus sorafenib in patients with advanced cancer. Clin Cancer Res off J Am Assoc Cancer Res. 2016 May 15 22(10):2368–2376. https://doi.org/10.1158/1078-0432.CCR-15-1681
   Google Scholar
• Lim HY, Merle P, Weiss KH, et al. Phase II studies with refametinib or refametinib plus sorafenib in patients with ras -mutated hepatocellular carcinoma. Clin Cancer Res off J Am Assoc Cancer Res. 2018 Oct 1 24(19):4650–4661. https://doi.org/10.1158/1078-0432.CCR-17-3588
   Google Scholar
• Kim R, Tan E, Wang E, et al. A phase I trial of trametinib in combination with sorafenib in patients with advanced hepatocellular cancer. Oncologist. 2020 Dec;25(12):e1893–e1899. DOI:https://doi.org/10.1634/theoncologist.2020-0759.
   PubMedGoogle Scholar
• Llovet JM, De Baere T, Kulik L, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Clin Pract Gastroenterol Hepatol. 2021 May;18(5):293–313. DOI:https://doi.org/10.1038/s41575-020-00395-0.
   Google Scholar
• Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 2011 Sep;4714:2117–2127. Oxford, England: 1990. DOI:https://doi.org/10.1016/j.ejca.2011.05.007
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM, Han G, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol. 2016 May;64(5):1090–1098. DOI:https://doi.org/10.1016/j.jhep.2016.01.012.
   PubMed Web of Science ®Google Scholar
• Meyer T, Fox R, Ma YT, et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2017 Aug;2(8):565–575. DOI:https://doi.org/10.1016/S2468-1253(17)30156-5.
   PubMed Web of Science ®Google Scholar
• Park JW, Kim YJ, Kim DY, et al. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: the phase III STAH trial. J Hepatol. 2019 Apr;70(4):684–691. DOI:https://doi.org/10.1016/j.jhep.2018.11.029.
   PubMed Web of Science ®Google Scholar
• Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020 Aug;69(8):1492–1501. DOI:https://doi.org/10.1136/gutjnl-2019-318934.
   PubMed Web of Science ®Google Scholar
• Brade AM, Ng S, Brierley J, et al. Phase 1 trial of sorafenib and stereotactic body radiation therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2016 Mar 1 94(3):580–587. https://doi.org/10.1016/j.ijrobp.2015.11.048
   Google Scholar
• Kudo M, Cheng AL, Park JW, et al. Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Lancet Gastroenterol Hepatol. 2018 Jan;3(1):37–46. DOI:https://doi.org/10.1016/S2468-1253(17)30290-X.
   PubMed Web of Science ®Google Scholar
• Kudo M, Han G, Finn RS, et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial. Hepatology. 2014 Nov;60(5):1697–1707. DOI:https://doi.org/10.1002/hep.27290.
   PubMed Web of Science ®Google Scholar
• Pokuri VK, Tomaszewski GM, Ait-Oudhia S, et al. Efficacy, safety, and potential biomarkers of sunitinib and transarterial chemoembolization (tace) combination in advanced hepatocellular carcinoma (HCC): phase II trial. Am J Clin Oncol. 2018 Apr;41(4):332–338. DOI:https://doi.org/10.1097/COC.0000000000000286.
   PubMed Web of Science ®Google Scholar
• Pinter M, Ulbrich G, Sieghart W, et al. Hepatocellular carcinoma: a phase ii randomized controlled double-blind trial of transarterial chemoembolization in combination with biweekly intravenous administration of bevacizumab or a placebo. Radiology. 2015 Dec;277(3):903–912. DOI:https://doi.org/10.1148/radiol.2015142140.
   PubMed Web of Science ®Google Scholar
• Daly JM, Kemeny N, Oderman P, et al. Long-term hepatic arterial infusion chemotherapy: anatomic considerations, operative technique, and treatment morbidity. Arch Surg. 1984;119(8):936–941. DOI:https://doi.org/10.1001/archsurg.1984.01390200054013.
   PubMedGoogle Scholar
• Kemeny N, Daly J, Oderman P, et al. Hepatic artery pump infusion: toxicity and results in patients with metastatic colorectal carcinoma. J Clin Oncol. 1984 Jun;2(6):595–600. DOI:https://doi.org/10.1200/JCO.1984.2.6.595.
   PubMed Web of Science ®Google Scholar
• Kudo M, Ueshima K, Yokosuka O, et al. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):424–432. DOI:https://doi.org/10.1016/S2468-1253(18)30078-5.
   PubMed Web of Science ®Google Scholar
• Kondo M, Morimoto M, Kobayashi S, et al. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial. BMC Cancer. 2019 Oct 15 19(1):954. https://doi.org/10.1186/s12885-019-6198-8
   Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015 Oct 22 373(17):1627–1639. https://doi.org/10.1056/NEJMoa1507643
   Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015 Jul 09 373(2):123–135. https://doi.org/10.1056/NEJMoa1504627
   Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015 Jan 22 372(4):320–330. https://doi.org/10.1056/NEJMoa1412082
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014 Apr 01 32(10):1020–1030. https://doi.org/10.1200/JCO.2013.53.0105
   Google Scholar
• Jenne CN, Kubes P. Immune surveillance by the liver. Nat Immunol. 2013 Oct;14(10):996–1006.
   PubMed Web of Science ®Google Scholar
• Makarova-Rusher OV, Medina-Echeverz J, Duffy AG, et al. The yin and yang of evasion and immune activation in HCC. J Hepatol. 2015 Jun;62(6):1420–1429. DOI:https://doi.org/10.1016/j.jhep.2015.02.038.
   PubMed Web of Science ®Google Scholar
• Brown ZJ, Heinrich B, Steinberg SM, et al. Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer. J Immunother Cancer. 2017 Nov 21 5(1):93. https://doi.org/10.1186/s40425-017-0298-2
   Google Scholar
• Sangro B, Gomez-Martin C, de la Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013 Jul;59(1):81–88. DOI:https://doi.org/10.1016/j.jhep.2013.02.022.
   PubMed Web of Science ®Google Scholar
• Rimassa L. Drugs in Development for Hepatocellular Carcinoma,Hepatol G. N Y 2018 Sep;149:542–544.Gastroenterology & hepatology
   Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. [2017 Jun 24];389(10088):2492–2502.
   PubMedGoogle Scholar
• Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022 Jan;23(1):77–90. DOI:https://doi.org/10.1016/S1470-2045(21)00604-5.
   PubMed Web of Science ®Google Scholar
• Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020 Jan 20 38(3):193–202. https://doi.org/10.1200/JCO.19.01307
   Google Scholar
• Vogel A, Merle P, Verslype C, et al. ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240. Ther Adv Med Oncol. 2021;13:17588359211039928.
   Google Scholar
• Qin S, Chen Z, Fang W, et al. Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): phase 3 KEYNOTE-394 study. J clin oncol. 2022;40(4_suppl):383. DOI:https://doi.org/10.1200/JCO.2022.40.4_suppl.383.
   Web of Science ®Google Scholar
• Moehler M, Heo J, Lee HC, et al. Vaccinia-based oncolytic immunotherapy pexastimogene devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter phase IIb trial (TRAVERSE). Oncoimmunology. 2019;8(8):1615817. DOI:https://doi.org/10.1080/2162402X.2019.1615817.
   PubMed Web of Science ®Google Scholar
• Escudier B, Faivre S, Van Cutsem E, et al. A phase II multicentre, open-label, proof-of-concept study of tasquinimod in hepatocellular, ovarian, renal cell, and gastric cancers. Target Oncol. 2017 Oct;12(5):655–661. DOI:https://doi.org/10.1007/s11523-017-0525-2.
   PubMed Web of Science ®Google Scholar
• Ryoo BY, Palmer DH, Park SR, et al. Efficacy and safety results from a phase 2, randomized, double-blind study of enzalutamide versus placebo in advanced hepatocellular carcinoma. Clin Drug Investig. 2021 Sep;41(9):795–808. DOI:https://doi.org/10.1007/s40261-021-01063-0.
   PubMedGoogle Scholar
• Harding JJ, Kelley RK, Tan B, et al. Phase Ib study of enzalutamide with or without sorafenib in patients with advanced hepatocellular carcinoma. Oncologist. 2020 Dec;25(12):e1825–e1836. DOI:https://doi.org/10.1634/theoncologist.2020-0521.
   PubMedGoogle Scholar
• Duffy AG, Ulahannan SV, Cao L, et al. A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib. United European Gastroenterol J. 2015 Oct;3(5):453–461. DOI:https://doi.org/10.1177/2050640615583587.
   PubMedGoogle Scholar
• Okusaka T, Ueno H, Ikeda M, et al. Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma. Hepatol Res. 2015 Dec;45(13):1283–1291. DOI:https://doi.org/10.1111/hepr.12504.
   PubMed Web of Science ®Google Scholar
• Okuda Y, Nakamura H, Yoshida K, et al. Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor. Cancer Sci. 2003 Dec;94(12):1034–1041. DOI:https://doi.org/10.1111/j.1349-7006.2003.tb01397.x.
   PubMedGoogle Scholar
• Yamamoto T, Nakamura H, Liu W, et al. Involvement of hepatoma-derived growth factor in the growth inhibition of hepatocellular carcinoma cells by vitamin K(2). J Gastroenterol. 2009;44(3):228–235. DOI:https://doi.org/10.1007/s00535-008-2304-4.
   PubMed Web of Science ®Google Scholar
• Haruna Y, Yakushijin T, Kawamoto S. Efficacy and safety of sorafenib plus vitamin K treatment for hepatocellular carcinoma: a phase II, randomized study. Cancer Med. 2021 Feb;10(3):914–922.
   PubMedGoogle Scholar
• Cheng AL, Kang YK, He AR, et al. Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: a phase 2 randomized study. J Hepatol. 2015 Oct;63(4):896–904. DOI:https://doi.org/10.1016/j.jhep.2015.06.001.
   PubMed Web of Science ®Google Scholar
• Lee FA, Zee BC, Cheung FY, et al. Randomized phase II study of the x-linked inhibitor of apoptosis (XIAP) antisense AEG35156 in combination with sorafenib in patients with advanced Hepatocellular Carcinoma (HCC). Am J Clin Oncol. 2016 Dec;39(6):609–613. DOI:https://doi.org/10.1097/COC.0000000000000099.
   PubMedGoogle Scholar
• Ciuleanu T, Bazin I, Lungulescu D, et al. A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma. Ann Oncol. 2016 Apr;27(4):680–687. DOI:https://doi.org/10.1093/annonc/mdw004.
   PubMedGoogle Scholar
• Abou-Alfa GK, Blanc JF, Miles S, et al. Phase II study of first-line trebananib plus sorafenib in patients with advanced hepatocellular carcinoma. Oncologist. 2017 Jul;22(7):780–e65. DOI:https://doi.org/10.1634/theoncologist.2017-0058.
   PubMed Web of Science ®Google Scholar
• Zhou F, Shang W, Yu X, et al. Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev. 2018 Mar;38(2):741–767. DOI:https://doi.org/10.1002/med.21455.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Puig O, Daniele B, et al. Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. J Hepatol. 2016 Aug;65(2):289–295. DOI:https://doi.org/10.1016/j.jhep.2016.04.004.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Yen CJ, Hsu CH, et al. Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC). Cancer Chemother Pharmacol. 2017 Feb;79(2):421–429. DOI:https://doi.org/10.1007/s00280-017-3241-9.
   PubMedGoogle Scholar
• El-Khoueiry AB, O’Donnell R, Semrad TJ, et al. A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2018 May;81(5):957–963. DOI:https://doi.org/10.1007/s00280-018-3553-4.
   PubMedGoogle Scholar
• Mokdad AA, Zhu H, Beg MS, et al. Efficacy and safety of bavituximab in combination with sorafenib in advanced hepatocellular carcinoma: a single-arm, open-label, phase II clinical trial. Target Oncol. 2019 Oct;14(5):541–550. DOI:https://doi.org/10.1007/s11523-019-00663-3.
   PubMed Web of Science ®Google Scholar
• Gordon SW, McGuire WP 3rd, Shafer DA, et al. Phase I study of sorafenib and vorinostat in advanced hepatocellular carcinoma. Am J Clin Oncol. 2019 Aug;42(8):649–654. DOI:https://doi.org/10.1097/COC.0000000000000567.
   PubMedGoogle Scholar
• Abou-Alfa GK, Qin S, Ryoo BY, et al. Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma. Ann Oncol. 2018 Jun 1 29(6):1402–1408. https://doi.org/10.1093/annonc/mdy101
   Google Scholar
• El Dika I, Lim HY, Yong WP, et al. An open-label, multicenter, phase i, dose escalation study with phase ii expansion cohort to determine the safety, pharmacokinetics, and preliminary antitumor activity of intravenous TKM-080301 in subjects with advanced hepatocellular carcinoma. Oncologist. 2019 Jun;24(6):747–e218. DOI:https://doi.org/10.1634/theoncologist.2018-0838.
   PubMedGoogle Scholar
• Greten TF, Abou-Alfa GK, Cheng AL, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. J Immunother Cancer. 2021 Sep;9(9):e002794. DOI:https://doi.org/10.1136/jitc-2021-002794.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Villanueva A, Marrero JA, et al. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology (Baltimore, Md). 2021 Jan;73 Suppl 1:158–191.
   Google Scholar
• Harding JJ, Nandakumar S, Armenia J, et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin Cancer Res off J Am Assoc Cancer Res. 2019 Apr 1;25(7):2116–2126. https://doi.org/10.1158/1078-0432.CCR-18-2293.
   Google Scholar
• Spencer CN, McQuade JL, Gopalakrishnan V, et al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science (New York, NY). 2021 Dec 24 374(6575):1632–1640. https://doi.org/10.1126/science.aaz7015
   Google Scholar
• Brown ZJ, Yu SJ, Heinrich B, et al. Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma. Cancer Immunol Immunother. 2018 Aug;67(8):1305–1315. DOI:https://doi.org/10.1007/s00262-018-2190-4.
   PubMed Web of Science ®Google Scholar
• Rahman M, Almalki WH, Alrobaian M, et al. Nanocarriers-loaded with natural actives as newer therapeutic interventions for treatment of hepatocellular carcinoma. Expert Opin Drug Deliv. 2021 Apr;18(4):489–513. DOI:https://doi.org/10.1080/17425247.2021.1854223.
   PubMed Web of Science ®Google Scholar
• Ma C, Kesarwala AH, Eggert T, et al. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature. 2016 Mar 10;531(7593):253–257. https://doi.org/10.1038/nature16969.
   Google Scholar
• Haber PK, Puigvehí M, Castet F, et al. Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002-2020). Gastroenterology. 2021 Sep;161(3):879–898. DOI:https://doi.org/10.1053/j.gastro.2021.06.008.
   PubMed Web of Science ®Google Scholar
• Ducreux M, Zhu AX, Cheng A-L, et al. IMbrave150: exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor). J clin oncol. 2021;39(15_suppl):4071. DOI:https://doi.org/10.1200/JCO.2021.39.15_suppl.4071.
   Web of Science ®Google Scholar
• Abou-Alfa GK, Chan SL, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J clin oncol. 2022;40(4_suppl):379. DOI:https://doi.org/10.1200/JCO.2022.40.4_suppl.379.
   Web of Science ®Google Scholar
• Kelley RK, Yau T, Cheng AL, et al. VP10-2021: cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): results from the randomized phase III COSMIC-312 trial. Ann Oncol. 2022;33(1):114–116. DOI:https://doi.org/10.1016/j.annonc.2021.10.008.
   Web of Science ®Google Scholar
• Shankaran V, Chennupati S, Sanchez H, et al. Clinical characteristics, treatment patterns, and healthcare costs and utilization for Hepatocellular Carcinoma (HCC) patients treated at a large referral center in Washington state 2007-2018. J Hepatocell Carcinoma. 2021;8:1597–1606.
   PubMed Web of Science ®Google Scholar
• Brown ZJ, Tsung A. Adjuvant treatment of hepatocellular carcinoma after resection. Hepatoma Res. 2021;7:68. .
   Google Scholar
• Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015 Oct;16(13):1344–1354. DOI:https://doi.org/10.1016/S1470-2045(15)00198-9.
   PubMed Web of Science ®Google Scholar
• Brown ZJ, Greten TF, Heinrich B. Adjuvant treatment of hepatocellular carcinoma: prospect of immunotherapy. Hepatology. 2019 Oct;70(4):1437–1442. DOI:https://doi.org/10.1002/hep.30633.
   PubMed Web of Science ®Google Scholar
• Decaens T, Barone C, Assenat E, et al. Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression. British journal of cancer. 2021;125(2):190–199.
   PubMedGoogle Scholar
• Okusaka T, Otsuka T, Ueno H, et al. Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment. Cancer science. 2016;107(12):1791–1799.
   PubMedGoogle Scholar
• Kelley RK, Gane E, Assenat E, et al. A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma. Clin Transl Gastroenterol. 2019;10(7):e00056.
   PubMedGoogle Scholar